Skip to main content
Shenyang Xingqi Pharmaceutical Co., Ltd. logo

Shenyang Xingqi Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300573 ISIN · CNE100002DV1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,236 across all filing types
Latest filing 2026-05-28 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 300573

About Shenyang Xingqi Pharmaceutical Co., Ltd.

https://www.sinqi.com

Shenyang Xingqi Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of ophthalmic medications. The company provides a comprehensive portfolio of eye care solutions targeting conditions such as myopia, dry eye syndrome, glaucoma, and ocular infections. Key products include low-dose atropine sulfate eye drops for slowing myopia progression in children, cyclosporine eye drops for dry eye, and various anti-infective and anti-inflammatory agents. The firm operates advanced manufacturing facilities and maintains a robust R&D pipeline focused on innovative drug delivery systems and therapeutic treatments for vision health. By integrating clinical research with industrial production, the company serves as a major provider of specialized ophthalmic pharmaceuticals, addressing diverse clinical needs in the field of ophthalmology.

Recent filings

Filing Released Lang Actions
关于收到深圳证券交易所《关于终止对沈阳兴齐眼药股份有限公司申请向特定对象发行股票审核的决定》的公告
Share Issue/Capital Change Classification · 75% confidence The document is an official company announcement regarding the withdrawal and termination of its application to issue A‐share stock to specific investors. This is a disclosure about a share issuance (private placement) process and its termination, which falls under a capital change/share issue announcement rather than a full report or regulatory certification.
2026-05-28 Chinese
关于终止向特定对象发行A股股票事项并撤回申请文件的公告
Share Issue/Capital Change Classification · 87% confidence The document is a corporate announcement from Shenyang Xingqi Eye Drops Co., Ltd. detailing the termination of a previously approved private placement of A‐shares and withdrawal of the related application. It describes board resolutions, independent director opinions, and background on the share issuance process. This fits squarely under a share issue/capital change announcement, as it concerns the company’s planned capital-raising via issuance of new shares to specific investors. Therefore, the filing is classified as a Share Issue/Capital Change (SHA).
2026-05-25 Chinese
第五届董事会第十七次会议决议公告
Share Issue/Capital Change Classification · 75% confidence The document is a formal board resolution announcement of the company’s decision to terminate a planned issuance of A‐shares to specific investors and withdraw the related application. It is not a change in board or management, nor an AGM materials or earnings release, but directly concerns a share issuance/capital change. Therefore, it falls under “Share Issue/Capital Change” (SHA).
2026-05-25 Chinese
关于获得药品注册证书的公告
Regulatory Filings Classification · 72% confidence The document is a formal public announcement by a listed pharmaceutical company regarding receipt of a drug registration certificate from the National Medical Products Administration. It does not contain financial statements, board changes, dividends, or share transactions. It is a routine regulatory compliance update. As such, it falls under the catch-all category for miscellaneous regulatory announcements (RNS).
2026-05-21 Chinese
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement of the company’s 2025 annual equity distribution (cash dividend and bonus share issuance), specifying dividend ratio, record date, ex-dividend date, distribution method, and related arrangements. This aligns precisely with a Notice of Dividend Amount.
2026-05-14 Chinese
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is an announcement of the shareholder meeting resolutions, providing detailed voting results for each proposal at the 2025 Annual General Meeting, including attendance, vote counts, percentages, and legal opinions. This matches the definition of “Declaration of Voting Results & Voting Rights Announcements.”
2026-05-13 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.